Published in Mult Scler on April 28, 2015
Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders (Momentum) | NCT04101058
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91
B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS One (2016) 0.80
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic. Curr Treat Options Neurol (2016) 0.79
Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. J Res Med Sci (2017) 0.75
Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder. Curr Treat Options Neurol (2015) 0.75
Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res (2017) 0.75
What's new in neuromyelitis optica? A short review for the clinical neurologist. J Neurol (2017) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord (2012) 1.62
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler (2009) 1.41
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler (2007) 1.37
Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol (2014) 1.27
Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol (2012) 1.05
Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol (2013) 1.01
Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int (2012) 0.90
The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci (2011) 0.89
Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler (2012) 0.83
Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arq Neuropsiquiatr (2013) 0.80
Therapeutic plasma exchange in neuromyelitis optica: a case series. J Clin Apher (2013) 0.78